650 related articles for article (PubMed ID: 33130698)
21. [A Case of Recurrent Breast Cancer with Drug-Induced Interstitial Pneumonia Triggered by the Switch from an Original to a Generic Aromatase Inhibitor].
Hirohashi Y; Kawashima Y; Shimonishi T; Koga Y; Miyake S; Hotta C; Yasushi K
Gan To Kagaku Ryoho; 2020 Dec; 47(12):1707-1709. PubMed ID: 33342988
[TBL] [Abstract][Full Text] [Related]
22. [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
Yoneda H; Shimizu Y; Masuda R
Gan To Kagaku Ryoho; 2020 May; 47(5):815-818. PubMed ID: 32408326
[TBL] [Abstract][Full Text] [Related]
23. PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
Matthews Hew T; Zuberi L
J Investig Med High Impact Case Rep; 2019; 7():2324709619864989. PubMed ID: 31375040
[TBL] [Abstract][Full Text] [Related]
24. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D; Bologna A; Cecere SC; De Matteis E; Scandurra G; Zamagni C; Arcangeli V; Artioli F; Bella M; Blanco G; Cardalesi C; Casartelli C; De Vivo R; Di Napoli M; Gisone EB; Lauria R; Lissoni AA; Loizzi V; Maccaroni E; Mangili G; Marchetti C; Martella F; Naglieri E; Parolin V; Ricciardi G; Ronzino G; Salutari V; Scarfone G; Secondino S; Spagnoletti I; Tasca G; Tognon G; Guarneri V
Support Care Cancer; 2020 May; 28(5):2435-2442. PubMed ID: 32048043
[TBL] [Abstract][Full Text] [Related]
25. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
[TBL] [Abstract][Full Text] [Related]
26. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
27. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
van der Noll R; Marchetti S; Steeghs N; Beijnen JH; Mergui-Roelvink MW; Harms E; Rehorst H; Sonke GS; Schellens JH
Br J Cancer; 2015 Jul; 113(3):396-402. PubMed ID: 26180927
[TBL] [Abstract][Full Text] [Related]
29. Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
Prescrire Int; 2017 Jan; 26(178):9-12. PubMed ID: 30730634
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of
Saito S; Nakazawa K; Nagahashi M; Ishikawa T; Akazawa K
Per Med; 2019 Nov; 16(6):439-448. PubMed ID: 31692405
[No Abstract] [Full Text] [Related]
32. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M; Kolesar J
Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
[TBL] [Abstract][Full Text] [Related]
33. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
36. Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
Sakamoto I; Hirotsu Y; Nakagomi H; Ikegami A; Teramoto K; Omata M
J Obstet Gynaecol Res; 2019 Mar; 45(3):743-747. PubMed ID: 30565790
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Yuan P; Shentu J; Xu J; Burke W; Hsu K; Learoyd M; Zhu M; Xu B
Cancer Chemother Pharmacol; 2019 May; 83(5):963-974. PubMed ID: 30887180
[TBL] [Abstract][Full Text] [Related]
39. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
40. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G; Milani M; Gobbi A; Dester M; Cappelletti MR; Allevi G; Aguggini S; Ravelli A; Gussago F; Cocconi A; Zanotti L; Senti C; Strina C; Bottini A; Generali D
Future Oncol; 2016 Oct; 12(19):2189-93. PubMed ID: 27324108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
